- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Acute myeloid leukaemia
- Meeting Date: March 2022
- Public Summary Document (PSD) March 2022 PBAC Meeting - (PDF 470KB)
- Public Summary Document (PSD) March 2022 PBAC Meeting - (Word 76KB)
Gilteritinib – March 2022
Gilteritinib: Tablet 40 mg (as fumarate); Xospata®
Last updated
1 July 2022